




Chinese Pharmaceutical Association  
Institute of Materia Medica, Chinese Academy of Medical Sciences

Acta Pharmaceutica Sinica B

[www.elsevier.com/locate/apsb](http://www.elsevier.com/locate/apsb)  
[www.sciencedirect.com](http://www.sciencedirect.com)



ORIGINAL ARTICLE

# Flavanols from the *Camellia sinensis* var. *assamica* and their hypoglycemic and hypolipidemic activities



Xin Wang<sup>†</sup>, Quan Liu<sup>†</sup>, Hongbo Zhu, Hongqing Wang, Jie Kang, Zhufang Shen, Ruoyun Chen<sup>\*</sup>

State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China

Received 21 October 2016; revised 29 November 2016; accepted 15 December 2016

## KEY WORDS

*Camellia sinensis* var. *assamica*;  
Pu-erh tea;  
Flavanol;  
Hypoglycemic;  
Hypolipidemic

**Abstract**  $\alpha$ -Glucosidase and lipase inhibitors play important roles in the treatment of hyperglycaemia and dyslipidemia. To identify novel naturally occurring inhibitors, a bioactivity-guided phytochemical research was performed on the pu-erh tea. One new flavanol, named (–)-epicatechin-3-*O*-(*Z*)-coumarate (**1**), and **16** known analogs (**2**–**17**) were isolated from the aqueous extract of the pu-erh tea. Their structures were determined by spectroscopic and chemical methods. Furthermore, the water extract of pu-erh tea and its fractions exhibited inhibitory activities against  $\alpha$ -glucosidases and lipases *in vitro*; compound **15** showed moderate inhibitory effect against sucrase with an IC<sub>50</sub> value of 32.5  $\mu$ mol/L and significant inhibitory effect against maltase with an IC<sub>50</sub> value of 1.3  $\mu$ mol/L. Compounds **8**, **10**, **11** and **15** displayed moderate activity against a lipase with IC<sub>50</sub> values of 16.0, 13.6, 19.8, and 13.3  $\mu$ mol/L, respectively.

© 2017 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

<sup>\*</sup>Corresponding author. Tel.: +86 10 63030807; fax: +86 10 83161622.

E-mail address: [rych@imm.ac.cn](mailto:rych@imm.ac.cn) (Ruoyun Chen).

Peer review under responsibility of Institute of Materia Medica, Chinese Academy of Medical Sciences and Chinese Pharmaceutical Association.

<sup>†</sup>These authors make equal contributions to this work.

## 1. Introduction


Type 2 diabetes mellitus (DM) is a metabolic disorder that is characterized by hyperglycemia caused by insulin resistance. It has become the third largest chronic noninfectious disease threatening the world. The classic symptoms include excess thirst, frequent urination, and constant hunger. Long-term complications from high blood sugar include heart disease, strokes, diabetic retinopathy and kidney failure. The use of herbal remedies to treat DM has been practiced since ancient times. Currently, more than 1000 plant species are being used as folk medicines to treat DM throughout the world<sup>1</sup>.

Tea is one of the most popular beverages consumed worldwide. According to the manufacturing process, Chinese commercial teas can be classified as green tea, yellow tea, white tea, oolong tea, black tea, and dark tea. Pu-erh tea is a kind of dark tea, which comes from “rough” *Camellia sinensis* (Linn) var. *assamica* (Masters) Kitamura (mao cha) in Yunnan province in China. The key production process of pu-erh tea is secondary fermentation, in which microorganisms play a very important role in producing the taste, color, fragrance, and functional components<sup>2</sup>. Pu-erh tea is not only a popular tea, but also a traditional Chinese medicine, which has many biological and biochemical effects, such as antiobesity<sup>3</sup>, antiviral<sup>4</sup>, antioxidative<sup>5</sup>, hepatoprotective<sup>6</sup>, hypoglycemic<sup>7</sup> and hypolipidemic<sup>8</sup>. In our research, we found that the water extract of pu-erh tea showed potential *in vitro* hypoglycemic and hypolipidemic effects. Bioassay-guided fractionation of these active extracts yielded one new flavanol (**1**) and 16 known compounds (**2–17**, Fig. 1), and the *in vitro*  $\alpha$ -glucosidase inhibitory activity and lipase inhibitory activity were evaluated. Herein, the purification, structural determination and biological assays of these isolates were discussed.

## 2. Results and discussion

### 2.1. Compounds from pu-erh tea

The EtOAc section of the water extract from the pu-erh tea was subjected to multiple column chromatographic purification steps and



**Figure 1** Chemical structure of compounds **1–17**.

further purified by preparative HPLC, affording one new flavanol (**1**) and 16 known compounds (Fig. 1). These compounds were identified as (–)-epicatechin-3-*O*-(*Z*)-coumarate (**1**), (–)-epicatechin-3-*O*-(*E*)-coumarate (**2**)<sup>9</sup>, (–)-epicatechin-3-*O*-(*E*)-caffeate (**3**)<sup>10</sup>, (+)-catechin (**4**)<sup>11</sup>, ampelopsin (**5**)<sup>12</sup>, (–)-epicatechin (**6**)<sup>11</sup>, (–)-epiafzelechin (**7**)<sup>13</sup>, (–)-epicatechin-3-*O*-gallate (**8**)<sup>11</sup>, (–)-epiafzelechin-3-*O*-gallate (**9**)<sup>11</sup>, (+)-catechin-3-*O*-gallate (**10**)<sup>14</sup>, (+)-epiafzelechin-3-*O*-gallate (**11**)<sup>15</sup>, epicatechin-3-*O*-*p*-hydroxybenzoate (**12**)<sup>16</sup>, (–)-epigallo-catechin (**13**)<sup>11</sup>, (±)-gallocatechin (**14**)<sup>11</sup>, (–)-epigallo-catechin-3-*O*-gallate (**15**)<sup>11</sup>, (+)-gallocatechin-3-*O*-gallate (**16**)<sup>17</sup> and (–)-epicatechin-3-*O*-(3''-*O*-methyl)-gallate (**17**)<sup>18</sup>.

Compound **1** was obtained as a pale amorphous powder and showed absorption bands for hydroxy group (3276 cm<sup>-1</sup>), aromatic double bond (1623, 1604 and 1514 cm<sup>-1</sup>), and carbonyl group (1709 cm<sup>-1</sup>) in the IR spectrum. Its molecular formula, C<sub>24</sub>H<sub>20</sub>O<sub>8</sub>, was deduced from HR-ESI-MS (*m/z* 437.1242 [M+H]<sup>+</sup>). In the <sup>1</sup>H NMR spectrum (Table 1), an ABX system of protons were observed at  $\delta_{\text{H}}$ : 6.88 (1H, d, *J*=1.8 Hz), 6.66 (1H, d, *J*=8.0 Hz) and 6.69 (1H, dd, *J*=1.8, 8.0 Hz); 2 methine proton signals at  $\delta_{\text{H}}$  5.79 (1H, d, *J*=1.8 Hz), 5.93 (1H, d, *J*=1.8 Hz) were assigned to the H-8 and H-6 in the A ring, respectively; 2 oxygenated methine proton signals at  $\delta_{\text{H}}$  4.99 (1H, br, s) and 5.32 (1H, br s), and 1 methylene proton signal at  $\delta_{\text{H}}$  2.91 (1H, dd, *J*=4.0, 17.5 Hz) and 2.64 (1H, br d, *J*=17.5 Hz) were ascribable to the C ring in flavanol; 2 *cis*-olefinic protons at  $\delta_{\text{H}}$  6.25 (1H, d, *J*=12.5 Hz) and 7.40 (1H, d, *J*=12.5 Hz) indicated the presence of *cis*-double bond. Four aromatic proton signals were assigned to a *p*-hydroxy benzene ring at  $\delta_{\text{H}}$  7.49 (2H, d, *J*=8.5 Hz, H-5'', -9'') and 6.75 (2H, d, *J*=8.5 Hz, H-6'', -8''). In the <sup>13</sup>C NMR spectrum (Table 1), 24 carbon signals, including 1 ketone carbon, 1 methylene carbon, 2 oxygenated methine carbons, 2 *cis*-olefinic carbons and 18 aromatic carbons, were also observed. In the HMBC spectrum (Fig. 2), correlations to a ketone carbonyl carbon at  $\delta_{\text{C}}$  165.2 (C-1'') from 2 *cis*-olefinic protons of H-2'' and H-3'' indicated the presence of  $\alpha,\beta$ -unsaturated ketone group. Correlations from H-3'' to C-1'', C-5'' and C-9'' and from H-2'' to C-1'' indicated the presence of a (*Z*)-coumaroyl moiety. The oxygenated methine proton H-3 was correlated with the carbonyl carbon signal at  $\delta_{\text{C}}$  165.2 (C-1''), confirming that the (*Z*)-coumaroyl moiety was connected to the 3-OH. Based on these data, the planar structure of compound **1** can be deduced.

Compound **1** has 2 chiral centers at C-2 and C-3. The 2,3-*cis* configuration of **1** was determined on the basis of a broad singlet at  $\delta_{\text{H}}$  4.99 for H-2 and an upfield shift of C-2 to  $\delta_{\text{C}}$  76.2<sup>19,20</sup>. The optical rotation  $\{[\alpha]_{\text{D}}^{20} -66.8$  (*c* 0.025, MeOH)} and CD data [217 ( $\Delta\epsilon$  -9.96), 267 ( $\Delta\epsilon$  +1.24) and 314 ( $\Delta\epsilon$  -4.05) nm, MeOH] of **1** were found to be similar to those of (–)-epicatechin-3-*O*-(*E*)-caffeate  $\{[\alpha]_{\text{D}}^{20} -175.5$  (*c* 0.21, MeOH); 233 ( $\Delta\epsilon$  -4.13), 273 ( $\Delta\epsilon$  +1.21) and 321 ( $\Delta\epsilon$  -4.37) nm, MeOH}<sup>10</sup>. Thus, the absolute configuration of compound **1** was determined to be 2*R* and 3*R*. The structure of compound **1** was determined as (–)-epicatechin-3-*O*-(*Z*)-coumarate.


### 2.2. *In vitro* hypoglycemic and hypolipidemic effects

$\alpha$ -Glucosidase inhibitors could restrain the liberation of glucose from oligosaccharides, thereby reducing the postprandial glucose levels and enhancing insulin responses. Such inhibitors, including acarbose and voglibose, are currently used clinically in combination with either diet or other anti-diabetic agents to control blood glucose levels. Natural resource provided a huge and highly

**Table 1**  $^1\text{H}$  NMR and  $^{13}\text{C}$  NMR spectroscopic data for compound **1**<sup>a</sup>.

No.	$\delta_{\text{H}}$	$\delta_{\text{C}}$	No.	$\delta_{\text{H}}$	$\delta_{\text{C}}$
<b>2</b>	4.99 (s)	76.2	<b>4'</b>		144.9
<b>3</b>	5.32 (br s)	67.7	<b>5'</b>	6.66 (d, $J=8.0$ Hz)	115.1
<b>4</b>	2.91 (dd, $J=4.0, 17.5$ Hz, H-a), 2.64 (br d, $J=17.5$ Hz, H-b)	25.5	<b>6'</b>	6.69 (dd, $J=1.8, 8.0$ Hz)	117.4
<b>5</b>		156.5	<b>1''</b>		165.2
<b>6</b>	5.93 (d, $J=1.8$ Hz)	95.5	<b>2''</b>	6.25 (d, $J=12.5$ Hz)	115.0
<b>7</b>		156.6	<b>3''</b>	7.40 (d, $J=12.5$ Hz)	143.6
<b>8</b>	5.79 (d, $J=1.8$ Hz)	94.3	<b>4''</b>		125.2
<b>9</b>		155.4	<b>5''</b>	7.49 (d, $J=8.5$ Hz)	132.5
<b>10</b>		97.2	<b>6''</b>	6.75 (d, $J=8.5$ Hz)	114.9
<b>1'</b>		129.2	<b>7''</b>		158.9
<b>2'</b>	6.88 (d, $J=1.8$ Hz)	114.2	<b>8''</b>	6.75 (d, $J=8.5$ Hz)	114.9
<b>3'</b>		144.9	<b>9''</b>	7.49 (d, $J=8.5$ Hz)	132.5

<sup>a</sup>Data were measured in DMSO- $d_6$  for **1** (500 MHz for  $^1\text{H}$  NMR and 125 MHz for  $^{13}\text{C}$  NMR).

**Figure 2** The key HMBC correlations of compound **1**.**Table 2** Inhibition effects of water extracts against  $\alpha$ -glucosidase and lipase  $\text{IC}_{50}$  ( $\mu\text{g/mL}$ ).

Sample	$\alpha$ -Glucosidase		Lipase
	Sucrase	Maltase	
1	49.3	4.72	9.69
2	14.4	11.4	7.52
3	50.1	22.4	12.42
4	>400	>400	>400

1: Water extract of pu-erh tea.  
 2: EtOAc fraction of water extract.  
 3: BuOH fraction of water extract.  
 4: Water fraction of water extract. Acarbose ( $\text{IC}_{50}$  value for sucrose:  $0.262 \mu\text{g/mL}$ , for maltase:  $0.084 \mu\text{g/mL}$ ) and Orlistat ( $\text{IC}_{50}$  value for lipase:  $0.006 \mu\text{g/mL}$ ) were used as positive control.

diversified chemical bank from which we could explore for potential therapeutic agents by bioactivity-driven screenings. Thus, a bioassay-guided approach was tried to identify active ingredients from pu-erh tea. To that end, the inhibitory activity of the water extract of pu-erh tea and its fractions on sucrose and maltase was measured. The results showed that the EtOAc fraction had moderate inhibitory activity with the  $\text{IC}_{50}$  values of  $14.4 \mu\text{g/mL}$  against sucrase and  $11.4 \mu\text{g/mL}$  against maltase, respectively (Table 2). Then, the inhibitory effects of compounds **1–17** were also measured using the same methods. (–)-Epigallo-catechin-3-*O*-gallate (**15**) showed moderate activity with  $\text{IC}_{50}$  values of  $32.5 \mu\text{mol/L}$  against sucrose and  $1.3 \mu\text{mol/L}$  against maltase, respectively (Table 3). In addition, compounds **2, 3, 5, 8–11**, and **13–16** displayed very weak inhibitory activities against

sucrase with  $\text{IC}_{50}$  values ranging from  $59.4$  to  $107.1 \mu\text{mol/L}$  (Table 3). In maltase inhibitory assay, compound **11** displayed moderate activity with an  $\text{IC}_{50}$  value of  $15.8 \mu\text{mol/L}$ , and compounds **1, 8, 9, 10, 12**, and **17** showed weak activities with  $\text{IC}_{50}$  values ranging from  $27.3$  to  $63.1 \mu\text{mol/L}$  (Table 3).

Lipase inhibitors could reduce the uptake of fat from food intake. The inhibitory activity of water extract and compounds **1–17** against a lipase was further evaluated. The results showed that the EtOAc fraction displayed strong activity with an  $\text{IC}_{50}$  value of  $7.52 \mu\text{g/mL}$  (Table 2), and compounds **8, 10**, and **15** displayed good activities with  $\text{IC}_{50}$  values of  $16.0$ ,  $13.6$ , and  $13.3 \mu\text{mol/L}$ , respectively (Table 3). And compounds **4–6, 9, 11, 13**, and **16** showed weak activities with  $\text{IC}_{50}$  values ranging from  $19.8$  to  $62.6 \mu\text{mol/L}$  (Table 3).

### 3. Conclusions

One new flavanol and 16 analogs were isolated from the water extract of pu-erh tea. The EtOAc fraction showed strong *in vitro* activity, which indicated that the functional materials were enriched in this fraction. The compounds isolated from the EtOAc fraction also showed inhibitory activity against  $\alpha$ -glucosidases and a lipase. Compounds **11** and **15** displayed good activity, which may have the potential to be developed as therapeutic agents. The current data suggested that the activity of catechin-type compounds might be associated with the galloyl group.

## 4. Experimental section

### 4.1. General experimental procedures

The optical rotations were measured using a Jasco P2000 polarimeter, UV spectra were determined using a Jasco V650 spectrophotometer (JASCO, Corporation, Tokyo, Japan). IR spectra were carried out on a Nicolet 5700 spectrophotometer with KBr disks (Thermo Electron Scientific Instruments Corp.).  $^1\text{H}$  NMR (500 MHz),  $^{13}\text{C}$  NMR (125 MHz), HSQC and HMBC spectra were run on a Mercury-500 with TMS as an internal standard (Varian, Palo Alto, CA, USA). HR-ESI-MS was performed on a 6520 Accurate-Mass Q-TOF LC/MS mass spectrometer. Sephadex LH-20 (Pharmacia, Uppsala, Sweden), silica gel (Qingdao Marine

**Table 3** Inhibition effects of isolated compounds against  $\alpha$ -glucosidase and lipase.

Compd.	Sucrase		Maltase		Lipase	
	Inhibition <sup>a</sup> (%)	IC <sub>50</sub> ( $\mu$ mol/L)	Inhibition <sup>a</sup> (%)	IC <sub>50</sub> ( $\mu$ mol/L)	Inhibition <sup>a</sup> (%)	IC <sub>50</sub> ( $\mu$ mol/L)
1	45.4	–	71.8	49.7	42.6	–
2	71.3	62.1	–	–	41.6	–
3	64.5	107.1	–	–	36.3	–
4	21.5	–	16.1	–	64.9	39.7
5	90.4	74.6	92.0	199.9	92.1	20.4
6	39.2	–	48.5	–	70.4	32.2
7	31.5	–	25.5	–	44.9	–
8	61.9	104.6	84.7	27.3	91.8	16.0
9	83.5	84.2	91.4	63.1	97.0	43.9
10	79.2	71.9	89.7	27.5	96.4	13.6
11	88.1	59.4	91.8	15.8	95.9	19.8
12	41.2	–	67.6	61.8	55.8	–
13	84.6	71.3	–	–	89.5	51.7
14	93.8	78.1	78.5	–	56.7	–
15	92.7	32.5	98.7	1.3	93.8	13.3
16	77.5	78.7	–	–	75.8	62.6
17	41.9	–	68.7	60.3	47.5	–

Acarbose (IC<sub>50</sub> value for sucrose: 0.97  $\mu$ mol/L, for maltase: 0.13  $\mu$ mol/L) and Orlistat (IC<sub>50</sub> value for lipase: 0.012  $\mu$ mol/L) were used as positive control.

– Not applicable.

<sup>a</sup>Inhibition at the concentration of 10<sup>-5</sup> mol/L.

Chemical Factory, 200–300 mesh), and RP-18 (Merck, 40–60  $\mu$ m) were used for CC and silica gel GF-254 (Qingdao Marine Chemical Factory, Qingdao, China) was used for TLC. The HPLC experiments were performed on a preparative YMC-Pack ODS-column (250 mm  $\times$  20 mm, 10  $\mu$ m, YMC, Kyoto, Japan) equipped with a Shimadzu SPD-6A UV spectrophotometric detector and an SPD-6AD pumping system (Shimadzu, Japan).

#### 4.2. Plant material

Dried pu-erh tea was purchased from “Da de sheng” tea-shop in Beijing, China, in August 2011 and authenticated by associate professor Lin Ma from Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College (IMM). A voucher specimen (S-2441) was deposited at the Herbarium of IMM.

#### 4.3. Extraction and isolation

##### 4.3.1. Isolation of **1**

Dried pu-erh tea (10.0 kg) was extracted three times with 20 L boiling water for 50 min. Then the solvent was evaporated and the resulting residue (3.4 kg) was suspended in H<sub>2</sub>O and extracted with EtOAc for 3 times, yielding a concentrated extract (1.4 kg). The EtOAc fraction (1.4 kg) was subjected to CC (silica gel; CHCl<sub>3</sub>–MeOH, 1:0–0:1) to obtain fractions A1–A6. Fr. A2 (127 kg) was submitted to repeated CC (silica gel, CHCl<sub>3</sub>–MeOH, 9:1–0:1) to afford 4 fractions, Fr. B1–B4. Fr. B2 (32 g) was further purified using CC (RP-C18 silica gel, MeOH–H<sub>2</sub>O, 5:95–1:0) to obtain fractions C1–C7. Fr. C3 (4.7 g) was separated by the RP-MPLC using an ODS column, and further purified by preparative HPLC to obtain **4** (85 mg), **5** (27 mg) and **6** (49 mg). Fr. C4 (3.2 g) was subjected to an NKA resin column (EtOH–H<sub>2</sub>O, 0:1–1:0), and further purified by Sephadex LH-20 CC and preparative HPLC to afford **7** (47 mg). Fr. C5 (2.1 g) and Fr. C6

(1.4 g) were subjected to Sephadex LH-20 CC (MeOH–H<sub>2</sub>O, 0:1–1:0) and further purified by preparative HPLC to obtain **8** (14 mg), **9** (46 mg), **10** (36 mg), **11** (21 mg), **12** (53 mg) and **17** (25 mg). Fr. B3 (22 g) was separated on a RP-C18 silica gel column eluting with MeOH–H<sub>2</sub>O (5:95–1:0) to afford 7 fractions, Fr. D1–D7. Fr. D3 (1.1 g) and Fr. D7 (4.8 g) were subjected to repeated CC purifications (NKA resin, EtOH–H<sub>2</sub>O 0:1–1:0; Sephadex LH-20, MeOH–H<sub>2</sub>O 0:1–1:0) and further purified by preparative HPLC to obtain **15** (12 mg), **16** (8 mg), **1** (19 mg) and **2** (6 mg). Using analogous separation and purification procedures as for Fr. B4 (13 g), Fr. B6 (18 g) afforded **3** (5 mg), **13** (23 mg) and **14** (50 mg).

##### 4.3.2. Identification of **1**

White amorphous powder, [ $\alpha$ ]<sub>D</sub><sup>20</sup>–66.8 (*c* 0.025, MeOH); UV (MeOH)  $\lambda_{\max}$  (log $\epsilon$ ) 208 (3.02), 314 (3.51) nm; IR (KBr)  $\nu_{\max}$  3276, 1709, 1623, 1604, 1514 cm<sup>-1</sup>; <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>, 500 MHz), and <sup>13</sup>C NMR (DMSO-*d*<sub>6</sub>, 125 MHz), see Table 1; positive ion mode HR-ESI-MS *m/z* 437.1242 [M+H]<sup>+</sup> (Calcd. for C<sub>24</sub>H<sub>21</sub>O<sub>8</sub> 437.1231).

#### 4.4. In vitro hypoglycemic and hypolipidemic activities

##### 4.4.1. Assessment of $\alpha$ -glucosidase inhibitory activity

Rat small intestinal brush border membrane vesicles were prepared and a suspension of this material in 0.1 mol/L phosphate buffer (pH 6.0) was used as the small intestinal  $\alpha$ -glucosidases of maltase, sucrase, isomaltase and trehalase. The enzyme suspension was diluted to hydrolyze sucrose to produce D-glucose in the following reaction. Reaction was performed in a 96-well plate. The substrate (sucrose: 100 mg/dL), test compounds and the enzyme in 0.1 mol/L phosphate buffer (pH 6.0, 0.2 mL) were incubated together at 37 °C. After 30 min of incubation, the plate was immediately heated to 80–85 °C for 3 min to stop the reaction, then cooled. Glucose concentration was

determined by the glucose oxidase method. The assay was performed in triplicates with five different concentrations around the IC<sub>50</sub> values. The IC<sub>50</sub> values were calculated from the dose–response curves, thus being obtained in the experiments.

#### 4.4.2. Assessment of lipase inhibitory activity

An enzyme buffer was prepared by the addition of 40 µL (5 mg/mL) of a solution of porcine pancreatic lipase in Tris buffer (pH 7.1) 20 µL of compounds or orlistat at the test concentration was mixed with the enzyme buffer, and incubated for 10 min at 37 °C. Then, 5 µL of the substrate solution (10 mg/mL triglyceride) was added and the enzymatic reaction was allowed to proceed for 60 min at 37 °C. Pancreatic lipase activity was determined by measuring the hydrolysis of triglyceride to glycerol, which was monitored at 500 nm using a plate reader. The inhibition of lipase activity was expressed as the percentage decreased in the optical density (OD) when porcine pancreatic lipase was incubated with the test compounds.

#### Acknowledgments

This work was supported by grants from National Mega–Project for Innovative Drugs (2012ZX09301002-002).

#### Appendix A. Supplementary material

Supplementary data associated with this paper can be found in the online version at <http://dx.doi.org/10.1016/j.apsb.2016.12.007>.

#### References

1. Marles RJ, Farnsworth NR. Antidiabetic plants and their active constituents. *Phytomedicine* 1995;**2**:137–89.
2. Lu HP, Gu JP, Lin Z, Guo L, Tan JF, Peng QH, et al. Advance in the study on the chemical composition and biological activity of Pu-erh Tea. *J Tea Sci* 2007;**27**:8–18.
3. Cao ZH, Gu DH, Lin QY, Xu ZQ, Huang QC, Rao H, et al. Effect of pu-erh tea on body fat and lipid profiles in rats with diet-induced obesity. *Phytother Res* 2011;**25**:234–8.
4. Wang D, Luo X, Zhong Y, Yang W, Xu MJ, Liu Y, et al. Pu-erh black tea extract supplementation attenuates the oxidative DNA damage and oxidative stress in Sprague–Dawley rats with renal dysfunction induced by subchronic 3-methyl-2-quinoxalin benzenevinylketo-1,4-dioxide exposure. *Food Chem Toxicol* 2012;**50**:147–54.
5. Tu SH, Chen MY, Chen LC, Mao YT, Ho CH, Lee WJ, et al. Pu-erh tea extract attenuates nicotine-induced foam cell formation in primary cultured monocytes: an in vitro mechanistic study. *J Agric Food Chem* 2016;**64**:3186–95.
6. Way TD, Lin HY, Kuo DH, Tsai SJ, Shieh JC, Wu JC, et al. Pu-erh tea attenuates hyperlipogenesis and induces hepatoma cells growth arrest through activating AMP-activated protein kinase (AMPK) in human HepG2 cells. *J Agric Food Chem* 2009;**57**:5257–64.
7. Du WH, Peng SM, Liu ZH, Shi L, Tan LF, Zou XQ. Hypoglycemic effect of the water extract of Pu-erh tea. *J Agric Food Chem* 2012;**60**:10126–32.
8. Lv HP, Zhu Y, Tan JF, Guo L, Dai WD, Lin Z. Bioactive compounds from Pu-erh tea with therapy for hyperlipidaemia. *J Fun Food* 2015;**19**:194–203.
9. Wu XD, Cheng JT, He J, Zhang XJ, Dong LB, Dong LB, et al. Benzophenone glycosides and epicatechin derivatives from *Malania oleifera*. *Fitoterapia* 2012;**83**:1068–71.
10. Liu F, Li FS, Feng ZM, Yang YN, Jiang JS, Li L, et al. Neuroprotective naphthalene and flavan derivatives from *Polygonum cuspidatum*. *Phytochemistry* 2015;**110**:150–9.
11. Zhou ZH, Yang CR. Chemical constituents of crude green tea, the material of Pu-er tea in Yunnan. *Acta Bot Yunnanica* 2000;**22**:343–50.
12. Lin YP, Chen TY, Tseng HW, Lee MH, Chen ST. Neural cell protective compounds isolated from *Phoenix hanceana* var. *formosana*. *Phytochemistry* 2009;**70**:1173–81.
13. Huang B, Huang ZY, Wu LB, Li W, Jiang B, Li SH. Chemical constituents from *Cassia agnes* Brenan. *Nat Prod Res Dev* 2012;**24**:437–9.
14. Ivanov SA, Nomura K, Malfanov IL, Sklyar IV, Pitsyn LR. Isolation of a novel catechin from *Bergenia* rhizomes that has pronounced lipase-inhibiting and antioxidative properties. *Fitoterapia* 2011;**82**:212–8.
15. Wan SB, Chan TH. Enantioselective synthesis of afezelechin and epiafezelechin. *Tetrahedron* 2004;**60**:8207–11.
16. Hashimoto F, Nonaka GI, Nishioka I. Tannins and related compounds LVI isolation of four new acylated flavan-3-ols from Oolong Tea. *Chem Pharm Bull* 1987;**35**:611–6.
17. Petereit F, Kolodziej H, Nahrstedt A. Flavan-3-ols and proanthocyanidins from *Cistus incanus*. *Phytochemistry* 1991;**30**:981–5.
18. Saijo R. Isolation and chemical structures of two new catechins from fresh tea leaf. *Agric Biol Chem* 1982;**46**:1969–70.
19. Slade D, Ferreira D, Marais JPI. Circular dichroism, a powerful tool for the assessment of absolute configuration of flavonoids. *Phytochemistry* 2005;**66**:2177–215.
20. Zeng XB, Qiu Q, Jiang CG, Jing YT, Qiu QF, He XJ. Antioxidant flavanes from *Livistona chinensis*. *Fitoterapia* 2011;**82**:609–14.